ArticleCureus2025
Adalimumab-Associated Transverse Myelitis Revealing Relapsing-Remitting Multiple Sclerosis in a Patient With Crohn's Disease: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 40-year-old woman with a background of Crohn's disease treated with azathioprine and adalimumab, who presented with acute right leg weakness, sensory loss, and urinary hesitancy. The MRI revealed a longitudinal cervical spinal cord lesion consistent with transverse myelitis (TM) and a supratentorial white matter lesion. The CSF analysis demonstrated unmatched oligoclonal bands, supporting central nervous system (CNS) demyelination. A prior episode of facial numbness in 2022 was retrospectively recognized as a previous relapse. These findings fulfilled the McDonald criteria for relapsing-remitting multiple sclerosis (RRMS). This case highlights the diagnostic challenges in patients with autoimmune disease receiving anti-tumor necrosis factor (TNF) therapy and underscores the importance of considering multiple sclerosis (MS) in such clinical contexts. The patient was treated with corticosteroids, while adalimumab was discontinued, and she demonstrated gradual neurological improvement over several weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.